Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > video interview
View:
Post by eric_a_su on Mar 18, 2021 11:05am

video interview

Comment by lscfa on Apr 23, 2021 10:53am
Interviewer asked what is it that investors are not getting? Part of the answer is confusion on whether Tetra is a cannabis stock or a biotech stock. I would add there is confusion on what is difference between CAUMZ and QIXLEEF. Are they both synthetic cannabis drugs? If so, why is Aphria the manufacturer? Does Aphria make synthetic cannabinoids? 
Comment by timetoscorebig on Apr 23, 2021 10:55am
This post has been removed in accordance with Community Policy
Comment by resistnothing on Apr 23, 2021 3:54pm
Will be a long while yet until we find out whether the drug works. He mentioned 30 days then changed it to 30 to 90 days!!! 
Comment by lscfa on Apr 23, 2021 5:04pm
More confusion: CAUMZ is a synthetic drug and QIXLEEF is a plant-based drug. Why? QIXLEEF has a fixed ratio of cbd:thc. What is CAUMZ mimicking as a synthetic? Why not make QIXLEEF synthetically to ensure a fixed ratio? Can a grower (Aphria) really guarantee consistency with tight tolerances?        
Comment by MiningGospel on Apr 23, 2021 5:16pm
There's something called the Entourage effect, where CBD +THC + Terpenes work in conjunction with each other to help with pain relief. Rafi Mechoulum has done a lot of work in this field
Comment by lscfa on Apr 23, 2021 7:36pm
Synthetic thc/CBD is still the way to go.    Nov 25, 2019 - QIXLEEF is the company’s first-generation cannabinoid therapeutic in development for treating advanced cancer patients with uncontrolled pain. The company believes a subset of the advanced cancer patient population prefers to consume cannabis in the traditional way, using dried flower bud as a drug product.  In early ...more  
Comment by lscfa on Apr 23, 2021 8:17pm
The co. is spending millions to prove that inhaled cannabis is better than opioids. If successful why would doctors prescribe QIXLEEF, especially if it is priced a lot higher than other medical cannabis? There's a risk doctors will piggyback off the QIXLEEF study and write their patients a note for some other medical cannabis with a similar THC:CBD ratio.  
Comment by WebSwinger on Apr 23, 2021 10:09pm
With QIXLEEF, I'm sure it can be covered under health insurance, so patiants get it for cheaper or for free in some cases. As for the other comments, tetra should have synthetic and non synthetic drugs. Diversity is good for many reasons of which i am to busy to list. 
Comment by MiningGospel on Apr 24, 2021 1:21am
This is completely incorrect. There is a pharmaceutical standard to achieve. Contaminants are a huge deal with pressed flower and TBP has dealt with this already. And insurance providers would cover the cost of the drug so no, your scenario is highly unethical and improbable
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities